lucas-vasques-9vnACvX2748-unsplash.jpg
040414_042.jpg

IVD Ancillary Agents

bbi-reagents-substrates-icon.svg

The complete Immunoassay reagent supplier

With the acquisition of DIARECT GmbH in June 2020, significant new product lines and skills have been added which considerably strengthens the BBI Solutions reagents portfolio.  With a range of autoimmune, allergy and specific infectious disease antigen products. In addition a range of Surmodics stabilisers, blockers and substrates are made available through BBI Solutions. 

The BBI Difference

Choice & Flexibility

Choice & Flexibility

Our core competencies include a comprehensive suite of reagents with custom development options, lateral flow development, diagnostic manufacturing services and smartphone reader technologies.

Quality System Certification

Quality System Certification

Each site follows strict Quality Control and product release protocols, which coupled with effective Quality Assurance processes ensure our products meet stringent product quality, safety and customer requirements.

Innovation

Innovation

Innovation is at the heart of our operations. The extensive breadth and depth of our products and services portfolio is testimony to the ongoing investment in our people and facilities.

Experience & Trust

Experience & Trust

BBI Solutions has been serving the global diagnostics industry for over 50 years and is the world’s largest independent producer of immuno-diagnostics reagents.

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox